Recombinant alpha-fetoprotein - rEVO Biologics/Merrimack

Drug Profile

Recombinant alpha-fetoprotein - rEVO Biologics/Merrimack

Alternative Names: ABI-001; AFP - GTC/Merrimack; MM-093; Recombinant human alpha fetoprotein; rhAFP - GTC/Merrimack

Latest Information Update: 21 Feb 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Atlantic Pharmaceuticals
  • Developer Merrimack Pharmaceuticals
  • Class Alpha fetoproteins; Recombinant proteins
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myasthenia gravis

Highest Development Phases

  • Discontinued Multiple sclerosis; Myasthenia gravis; Psoriasis; Rheumatoid arthritis; Uveitis

Most Recent Events

  • 04 Jan 2013 GTC Biotherapeutics is now called rEVO Biologics
  • 11 Mar 2011 Discontinued - Phase-I for Multiple sclerosis in United Kingdom (SC)
  • 11 Mar 2011 Discontinued - Phase-I for Myasthenia gravis in United Kingdom (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top